Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methicillin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 0.81 |
| ▸ | ABCB11 | O95342 | 4/20 | 0.63 |
| ▸ | HRH1 | P35367 | 1/20 | 0.59 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.57 |
| ▸ | RECQL | P46063 | 3/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | TEK | Q02763 | 1/20 | 0.57 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | RARB | P10826 | 1/20 | 0.53 |
| ▸ | RARG | P13631 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methicillin SCHEMBL6930787 | 1.00 | PTGS1 (1.00) | PTGS1PDE3ALMNAABCB11HRH1 | |
| Methicillin SCHEMBL30686387 | 1.00 | PTGS1 (1.00) | PTGS1PDE3ALMNAABCB11HRH1 | |
| Methicillin SCHEMBL15544897 | 1.00 | PTGS1 (1.00) | PTGS1PDE3ALMNAABCB11HRH1 | |
| Methicillin SCHEMBL4548766 | 1.00 | PTGS1 (1.00) | PTGS1PDE3ALMNAABCB11HRH1 | |
| Methicillin SCHEMBL34136 | 0.99 | PTGS1 (0.98) | PTGS1PDE3ALMNAABCB11HRH1 | |
| Methicillin SCHEMBL11207170 | 0.99 | PTGS1 (0.98) | PTGS1PDE3ALMNAABCB11HRH1 | |
| Methicillin SCHEMBL29184234 | 0.99 | PTGS1 (0.98) | PTGS1PDE3ALMNAABCB11HRH1 | |
| Methicillin SCHEMBL10743888 | 0.99 | PTGS1 (0.98) | PTGS1PDE3ALMNAABCB11HRH1 | |
| Methicillin SCHEMBL28422658 | 0.99 | PTGS1 (0.98) | PTGS1PDE3ALMNAABCB11HRH1 | |
| Methicillin SCHEMBL28904039 | 0.98 | PTGS1 (0.96) | PTGS1PDE3ALMNAABCB11HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 59895 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3752148-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING TEIXOBACTIN AND A PEGYLATED PHOSPHOLIPID, AND THEIR USE IN TREATING BACTERIAL INFECTION | NOVOBIOTIC PHARMACEUTICALS LLC (US) | 2026-05-27 | — | — | EP | claimed |
| US-12635687-B2 | Aqueous hop extracts and their use as antimicrobial agents | Nature Recombined Sciences Inc. (CA) | 2026-05-26 | — | — | US | claimed |
| US-12638447-B2 | Compositions, methods, and systems for detecting methicillin-resistant Staphylococcus aureus | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2026-05-26 | — | — | US | claimed |
| US-12638414-B2 | Device, procedure and system for detecting bacterial pathogens including methicillin-resistant Staphylococcus aureus or clostridium difficile | Kern, III, Clifford H. (US) | 2026-05-26 | — | — | US | claimed |
| CN-122080166-A | Sea lion source antibacterial peptide for selectively targeting gram-negative drug-resistant bacteria and application thereof | — | 2026-05-26 | — | — | CN | claimed |
| CN-122081244-A | Novel methicillin-resistant staphylococcus aureus phage and application thereof | — | 2026-05-26 | — | — | CN | claimed |
| CN-122075407-A | Sulfcloxazine sodium methicillin suspension, preparation method and application thereof | — | 2026-05-26 | — | — | CN | claimed |
| US-12637481-B2 | Boronic acid derivatives and therapeutic uses thereof | QPEX BIOPHARMA, INC. (US) | 2026-05-26 | — | — | US | claimed |
| CN-121779503-B | Antibacterial peptide and application thereof | 重庆理工大学 | 2026-05-22 | — | — | CN | claimed |
| WO-2026107387-A1 | SYSTEMS AND METHODS FOR MICROBIAL DNA AND RNA DETECTION | DELVE BIO, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| EP-0026409-A1 | Combinations of active ingredients, pharmaceutical preparations, as well as their preparation | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1981-04-08 | — | — | EP | claimed |
| US-4239745-A | INCUBATION WITH TAGGED ANTIBIOTIC AND ANTIBIOTIC SENSITIVE CELLS | PENICILLIN ASSAYS, INC. (US) | 1980-12-16 | — | — | US | claimed |
| US-4236211-A | Method and apparatus for determining the minimum concentration of antibiotic necessary to at least inhibit microorganism growth | PFIZER INC. (US) | 1980-11-25 | — | — | US | claimed |
| EP-0010846-A1 | Method and apparatus for determining the minimum concentration of antibiotic to inhibit microorganism growth | WARNER-LAMBERT COMPANY (US) | 1980-05-14 | — | — | EP | claimed |
| US-4199566-A | DERIVATIVES OF PENICILLANIC ACID | TOYAMA CHEMICAL COMPANY, LIMITED (JP) | 1980-04-22 | — | — | US | claimed |
| US-4175125-A | USING HALOGENATED PHENYLTHIOACETAMIDO CEPHALOSPORANIC ACID DERIVAT | ELI LILLY AND COMPANY (US) | 1979-11-20 | — | — | US | claimed |
| US-4143134-A | BACTERICIDES, ANTIBIOTIC POTENTIATORS | HOFFMANN-LA ROCHE INC. (US) | 1979-03-06 | — | — | US | claimed |
| US-4134972-A | OLIGOPEPTIDES | HOFFMANN-LA ROCHE INC. (US) | 1979-01-16 | — | — | US | claimed |
| US-4131672-A | HALOGENATED PHENYLTHIOACETAMIDO CEPHALOSPORANIC ACIDS | ELI LILLY AND COMPANY (US) | 1978-12-26 | — | — | US | claimed |
| US-4127649-A | PEPTIDES | HOFFMANN-LA ROCHE INC. (US) | 1978-11-28 | — | — | US | claimed |